SYNTHETIC HELPER PEPTIDE VACCINES FOR PATIENTS WITH STAGE IV MELANOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该方案旨在评估一种疫苗的安全性和免疫原性，该疫苗由6个黑色素瘤辅助肽和GM-CSF作为佐剂用于晚期黑色素瘤患者。这项研究的目的是确定疫苗(A)是否安全，(B)是否会在哨兵免疫的结节和外周血中引起免疫反应，以及(C)是否会导致迟发性超敏反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol was designed to assess the safety and immunogenicity of a vaccine comprised of six melanoma helper peptides plus GM-CSF in adjuvant in patients with advanced melanoma. The objectives of this study are to determine if the vaccine (a) is safe, (b) will result in immune responses in the sentinel immunized node and peripheral blood, and (c) will result in delayed-type hypersensitivity response.